
New Director Appointment

Adelaide, Australia, 31 August 2020 – Nova Eye Medical Limited (ASX: EYE)(Nova Eye Medical or the Company), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces the appointment of Mr Tom Spurling as a Director of the Company, effective 31 August 2020.

Mr Spurling previously served as the Chief Executive Officer of Ellex Medical Lasers from 2011-2019 and currently acts as a consultant to Nova Eye Medical. Tom has close to 30 years of senior executive experience serving in a range of roles.

Mr Victor Previn, Executive Chairman of Nova Eye Medical said “Tom has acted as a consultant to the Company for the last 16 months, advising senior management and the Board on the sale of the Laser & Ultrasound business to Lumibird, which was completed in June 2020. Additionally, he has been assisting the Company in framing our clinical, regulatory and commercial strategy for 2RT® for the important U.S. market. Tom’s knowledge of the business will be invaluable and on behalf of the Board, we welcome Tom as a Director of Nova Eye Medical.”

This release dated 31 August 2020 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Victor Previn
Executive Chairman
Nova Eye Medical Limited
vprevin@nova-eye.com

Media

Kate Hunt
Head of Marketing
Nova Eye Medical Limited
W +61 404 080 679
khunt@nova-eye.com

Investors

Dr. Tom Duthy
Investor Relations & Corporate Development
Nova Eye Medical Limited
W +61 402 493 727
tduthy@nova-eye.com

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com